Informations générales (source: ClinicalTrials.gov)
High-flow Nasal Cannula Nebulization of Beta 2 Adrenergic Agonist During Acute Exacerbation of Chronic Obstructive Pulmonary Disease (OPTINEB)
Interventional
Phase 3
Poitiers University Hospital (Voir sur ClinicalTrials)
janvier 2019
avril 2020
29 juin 2024
High-flow nasal cannula is an oxygenation technique increasingly used for patients
admitted for acute respiratory failure. Literature essentially concerns "de novo" acute
hypoxemic failure and the interest of high-flow during take care of chronic obstructive
pulmonary disease patients is few studied. Physiological studies reported potential
benefits of high-flow nasal cannula oxygenation in chronic obstructive pulmonary disease
patients including dead space clearance and decrease of respiratory, which lead to
decrease work of breathing. As inhaled bronchodilators are part of treatment of chronic
obstructive pulmonary disease exacerbation, nebulization could be also provided through
high-flow nasal cannula oxygen therapy. The aim of our study is to determine whether a
beta-2 agonist nebulization administered through High-flow nasal cannula is efficient to
improve spirometry of patients for admitted hronic obstructive pulmonary disease
exacerbation.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| C.H.U. de Poitiers - 86000 - Poitiers - France | Jean-Pierre Frat, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Arterial pH over 7.25,
- Respiratory rate under 35 breaths/mn
- Glasgow Coma Scale equal to 15,
- indication of beta-2 agonist nebulization less than 8 per day (time between two
nebulization more than 3 hours),
- NIV sessions spaced more than 6 hours.
- Arterial pH over 7.25,
- Respiratory rate under 35 breaths/mn
- Glasgow Coma Scale equal to 15,
- indication of beta-2 agonist nebulization less than 8 per day (time between two
nebulization more than 3 hours),
- NIV sessions spaced more than 6 hours.
- Urgent endotracheal intubation;
- Contraindication to beta 2 adrenergic agonist;
- Another organ failure (hemodynamic and neurological instability);
- Cardioselective beta-blocker during treatment of copd exacerbation;